MX2024003775A - Metodo de administracion segura del conjugado de fosfopeptido de tau. - Google Patents
Metodo de administracion segura del conjugado de fosfopeptido de tau.Info
- Publication number
- MX2024003775A MX2024003775A MX2024003775A MX2024003775A MX2024003775A MX 2024003775 A MX2024003775 A MX 2024003775A MX 2024003775 A MX2024003775 A MX 2024003775A MX 2024003775 A MX2024003775 A MX 2024003775A MX 2024003775 A MX2024003775 A MX 2024003775A
- Authority
- MX
- Mexico
- Prior art keywords
- safe administration
- tau phosphopeptide
- tau
- conjugate
- phosphopeptide conjugate
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6068—Other bacterial proteins, e.g. OMP
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163261793P | 2021-09-29 | 2021-09-29 | |
| PCT/US2022/077279 WO2023056369A1 (en) | 2021-09-29 | 2022-09-29 | Method of safe administration of tau phosphopeptide conjugate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024003775A true MX2024003775A (es) | 2024-04-11 |
Family
ID=85783654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024003775A MX2024003775A (es) | 2021-09-29 | 2022-09-29 | Metodo de administracion segura del conjugado de fosfopeptido de tau. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250049900A1 (enExample) |
| EP (1) | EP4408864A4 (enExample) |
| JP (1) | JP2024538615A (enExample) |
| KR (1) | KR20240082368A (enExample) |
| CN (1) | CN118613496A (enExample) |
| AU (1) | AU2022356435A1 (enExample) |
| CA (1) | CA3233247A1 (enExample) |
| MX (1) | MX2024003775A (enExample) |
| WO (1) | WO2023056369A1 (enExample) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013500326A (ja) * | 2009-07-30 | 2013-01-07 | ファイザー バクシーンズ エルエルシー | 抗原性タウペプチドおよびその使用 |
| CN111787942B (zh) * | 2017-10-25 | 2024-03-29 | 杨森制药公司 | 磷酸化Tau肽的组合物及其用途 |
| JOP20210284A1 (ar) * | 2019-04-24 | 2023-01-30 | Janssen Pharmaceuticals Inc | الإعطاء غير المتجانس للقاحات تاو |
-
2022
- 2022-09-29 JP JP2024519447A patent/JP2024538615A/ja active Pending
- 2022-09-29 KR KR1020247013320A patent/KR20240082368A/ko active Pending
- 2022-09-29 MX MX2024003775A patent/MX2024003775A/es unknown
- 2022-09-29 CA CA3233247A patent/CA3233247A1/en active Pending
- 2022-09-29 EP EP22877579.7A patent/EP4408864A4/en active Pending
- 2022-09-29 US US18/696,444 patent/US20250049900A1/en active Pending
- 2022-09-29 WO PCT/US2022/077279 patent/WO2023056369A1/en not_active Ceased
- 2022-09-29 CN CN202280078258.6A patent/CN118613496A/zh active Pending
- 2022-09-29 AU AU2022356435A patent/AU2022356435A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3233247A1 (en) | 2023-04-06 |
| WO2023056369A1 (en) | 2023-04-06 |
| US20250049900A1 (en) | 2025-02-13 |
| EP4408864A1 (en) | 2024-08-07 |
| KR20240082368A (ko) | 2024-06-10 |
| JP2024538615A (ja) | 2024-10-23 |
| EP4408864A4 (en) | 2025-09-03 |
| CN118613496A (zh) | 2024-09-06 |
| AU2022356435A1 (en) | 2024-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024004846A (es) | Compuesto tetraciclico que contiene nitrogeno, metodo de preparacion del mismo y uso medico del mismo. | |
| MX2017014127A (es) | Conjugados proteina-polisacarido de estreptococo grupo b, metodos para producir conjugados, composiciones inmunogenas que comprenden conjugados y sus usos. | |
| CL2017002636A1 (es) | Composiciones que comprenden una combinación de un anticuerpo anti muerte programada 1 (pd-1) y otro anticuerpo. | |
| MX2018011348A (es) | Composiciones de extractos naturales y uso de los mismos para prevenir o tratar enfermedades. | |
| CO2019000214A2 (es) | Vacuna contra virus de bronquitis infecciosa | |
| AR095338A1 (es) | Método de tratamiento no tóxico para la abstinencia de drogas | |
| JP2018505882A5 (enExample) | ||
| CL2022002566A1 (es) | Combinaciones de brimonidina de dosis baja y usos de las mismas. (solicitud divisional de 201903572) | |
| MX2020003756A (es) | Composiciones y metodos para obtener una respuesta inmune contra clostridium difficile. | |
| MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
| CL2021000882A1 (es) | Formulaciones y métodos para tratar las nauseas y vómitos inducidos por la quimioterapia. | |
| AR110800A1 (es) | MÉTODOS PARA AUMENTAR EN PLASMA SANGUÍNEO LA 2-DESOXIURIDINA (dUrd) Y LA INHIBICIÓN DE LA TIMIDILATO SINTASA | |
| CL2021002107A1 (es) | Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria. | |
| MX2023004832A (es) | Método de administración segura del anticuerpo anti-tau. | |
| MX2015013115A (es) | Nuevos regimenes de dosificacion de celgosivir para el tratamiento de dengue. | |
| MX2024003775A (es) | Metodo de administracion segura del conjugado de fosfopeptido de tau. | |
| AR101901A1 (es) | Tratamiento de enfermedades neurodegenerativas con una combinación de laquinimod y fingolimod | |
| CO2022016537A2 (es) | Vacuna inactivada para sars-cov-2 y preparación de la misma | |
| BR112018072298A2 (pt) | tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase | |
| CL2013002829A1 (es) | Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv. | |
| MX2022011651A (es) | Composicion farmaceutica para tratamiento de diabetes. | |
| CO2024004886A2 (es) | Composiciones de gel inmunógenas | |
| CO2022007006A2 (es) | Vacuna triple contra avibacterium paragallinarum y el virus de la encefalomielitis aviar y el virus de la viruela aviar | |
| AR117784A1 (es) | Tratamiento del sobreuso de medicación para el dolor de cabeza utilizando anticuerpos anti-cgrp o anti-cgrp-r | |
| MX2018010367A (es) | Titulacion de cebranopadol. |